Daiichi Sankyo

This is an early-stage study to test the safety and initial effects of an experimental drug called DS-1001b in adults with recurrent glioma, a type of brain tumor. The drug specifically targets tumors that have a particular genetic change called an IDH1-R132 mutation. The main go…

This study tested whether a new drug called DS-8201a works better than the current standard treatment (T-DM1) for advanced HER2-positive breast cancer that has worsened despite previous therapies. It involved 524 adults whose cancer had spread and could not be surgically removed.…

This study is testing a new targeted drug called ifinatamab deruxtecan for people with extensive-stage small cell lung cancer that has worsened after previous treatments. The trial aims to find the best dose and see how well the drug shrinks tumors and controls the cancer. About …

This large study is testing whether adding a new targeted drug (datopotamab deruxtecan) to standard immunotherapy helps people with advanced non-small cell lung cancer live longer without their cancer getting worse. It will compare this new combination to the current standard tre…

This study is testing an experimental drug called trastuzumab deruxtecan for people with advanced HER2-positive stomach or gastroesophageal cancer that has continued to grow despite initial treatment. It will compare this new drug against a standard combination therapy to see whi…

This is the first study in humans testing a new drug called DS-1055a. It aims to find a safe dose and check for side effects in 40 adults with advanced solid tumors that have returned or stopped responding to available treatments. The main goal is to understand how the body handl…

This study compares an experimental drug called DS-8201a against standard treatments for advanced breast cancer that has low levels of a protein called HER2. It involves 557 people whose cancer has spread or cannot be removed by surgery and who have already tried other treatments…

This study is testing a new drug called U3-1402 (HER3-DXd) for people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors in patients whose cancer has worsened despi…

This study is testing whether a new drug called DS-1062a works better than the standard chemotherapy drug docetaxel for people with advanced non-small cell lung cancer that has worsened after previous treatments. It will involve about 605 adults whose cancer has spread and who ha…

This study is testing an experimental drug called patritumab deruxtecan for people with advanced lung cancer that has a specific genetic change (EGFR mutation) and has worsened after trying at least two standard treatments. The main goal is to see how well the drug shrinks tumors…

This study is testing an oral drug called valemetostat in adults whose peripheral T-cell lymphoma has come back or hasn't responded to prior treatments. The main goal is to see if the drug safely shrinks tumors and for how long. It includes 155 participants and focuses on measuri…

This study is testing a new combination of two cancer drugs, trastuzumab deruxtecan and pembrolizumab, for people with advanced breast or lung cancer. The first part aims to find a safe dose, and the second part will see how well the combination works to control the cancer. It is…

This study aims to understand how doctors currently treat advanced triple-negative breast cancer in real-world settings outside the United States. Researchers will review medical records of 760 patients from Canada, the UK, France, and Spain to document treatment patterns and pat…